RBC Capital Assumes Sarepta Therapeutics (SRPT) at Outperform

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/26/2026

1. ORCL
2. SPY
3. LLY
4. META
5. FICO
6. TSLA
7. SPCX
8. MSFT
9. AZN
10. FLG

Go back to RBC Capital Assumes Sarepta Therapeutics (SRPT) at Outperform

Sarepta Therapeutics (SRPT) PT Raised to $77 at Leerink Partners; 'Ability to Dose Escalate Is Key'

January 19, 2018 8:49 AM EST

Leerink Partners raised its price target on Sarepta Therapeutics (NASDAQ: SRPT) to $77.00 (from $72.00) while maintaining an Outperform rating.

Analyst Joseph Schwartz commented, "Given Sarepta's enhanced emphasis on R&D now, we have taken a closer look at the company's use of peptide-conjugated phosphorodiamidate... More